Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2015-08-05
- Target Recruit Count
- 177
- Registration Number
- NCT00949598
- Locations
- 🇫🇷
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00903162
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Newton Wellesley Hospital, Newton, Massachusetts, United States
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 540
- Registration Number
- NCT00902954
- Locations
- 🇨🇳
Jinsong Lu, Shanghai, Shanghai, China
Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 44
- Registration Number
- NCT00893061
- Locations
- 🇫🇷
Centre Paul Strauss, Strasbourg, France
🇫🇷Centre Eugene Marquis, Rennes, France
🇫🇷Centre Oscar Lambret, Lille, France
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00880009
- Locations
- 🇭🇺
Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly, Budapest, Hungary
🇺🇸American Institute of Research, Whittier, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00856050
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Antagonist/Letrozole in Poor Responders
- Conditions
- Interventions
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2013-12-23
- Lead Sponsor
- Yazd Research & Clinical Center for Infertility
- Target Recruit Count
- 120
- Registration Number
- NCT00823004
- Locations
- 🇮🇷
Research and clinical center for infertility, Yazd, Iran, Islamic Republic of
Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Center for Human Reproduction
- Registration Number
- NCT00804960
- Locations
- 🇺🇸
Center for Human Reproduction, New York, New York, United States
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT00796107
Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2009-08-10
- Lead Sponsor
- Antisoma Research
- Target Recruit Count
- 110
- Registration Number
- NCT00770354
- Locations
- 🇷🇺
State Medical Institution, Pyatigorsk, Stavropol, Russian Federation
🇷🇺State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Oncological Center, Chelyabinsk, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.